Clinical trial
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed…
NCT00317200 · Hoosier Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00317200 |
|---|---|
| Title | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer |
| Official title | Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study |
| Lead sponsor | Hoosier Cancer Research Network, Other |
| Collaborators | Genentech, Inc. Industry Walther Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, Bevacizumab |
| Enrollment | 34 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Apr 24, 2006 |
| Last update posted | May 2, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: